San Diego, February 26

Welcome to hubXchange’s San Diego Antibody Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Handlery Hotel San Diego, 950 Hotel Circle North, San Diego CA 92108


  • Different criteria for target selection depending on the type of biologic modality
  • Autoantibody profiling of elite responders to discover novel targets and antibodies for cancer treatment
  • Key considerations for target selection and proposal
  • Discovery of pharmacollogically active antibodies that target challenging membrane proteins
  • Technology landscape for affinity analysis in antibody characterization for drug discovery
  • Challenges of using single domain antibodies as new modalities of multifunctional biologics
  • Determining the right bi-specific platform to generate bi-specific antibodies
  • Enhancing complex antibody-based modalities through in silico and lab-based methods
  • Multi-specific agonists for immuno-oncology. Challenges and opportunities in protein engineering
  • Navigating the discovery and development of bispecific antibodies (bsAbs) in therapeutics
  • Developing therapies to target multiple immune pathways
  • Persistence and Immunotherapy

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Titles and Bullets
8:00 – 8:30
8:30 – 9:00

Opening Address & Keynote Presentation

Harnessing the Power of Biological Intelligence and Artificial Intelligence to Accelerate Therapeutic Antibody Discovery

Eric Vajda is Vice President, Preclinical Research and Development at OmniAb. Dr. Vajda has more than 20 years of biopharma experience in pharmacology and preclinical development. Prior to OmniAb, Dr. Vajda was VP of Preclinical R&D at Ligand Pharmaceuticals. From 2002-2022, Dr. Vajda had leadership roles in multiple research projects at Ligand including the Selective Androgen Receptor Modulator (SARM) program, Interleukin-1 Receptor Associated Kinase 4 (IRAK4) program, and Glucagon Receptor Antagonist program. Prior to Ligand, Dr. Vajda was a Sr. Research Scientist at Bayer Corporation in the osteoporosis and cancer research. Dr. Vajda has served as a reviewer for multiple scientific journals and has authored more than 50 scientific publications and presentations. Dr. Vajda earned a BS from Yale University and PhD in Bioengineering from the University of Utah, and also held a research fellowship position at the Klinik Wilhelm Schulthess in Zürich, Switzerland and completed postdoctoral research in the Division of Radiobiology at the University of Utah.
Eric Vajda
9:05 – 10:05
Different criteria for target selection depending on the type of biologic modality

Key issues in target selection:

  • therapeutic index,
  • resistance mechanisms,
  • OMICs platforms for target selection
Milutinovic has 20 years of experience in diverse oncology research areas and has been involved in driving several biologic and small molecule therapeutics into FIH studies. Deep understanding and experience in evaluating different target classes and resistance mechanisms has enabled her to identify strongly synergistic drug combinations and influence clinical strategies for patients with unmet needs.
Snezana Milutinovic
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning refreshments
11:20 – 12:20
Autoantibody profiling of elite responders to discover novel targets and antibodies for cancer treatment
  • How many blockbuster cytotoxic targets lie undiscovered? How many more Herceptins?
  • How do you find them? Sequencing? Mass spec? Autoantibody seromics?
  • Can knockout-like autoantibodies vs cytokines, other surface proteins help us discover novel checkpoints?
  • Is there a good ROI to “mine”; immunity similar to companies like
  • OncoResponse? Do you know of any?
  • What are the best approaches / platforms for profiling autoantibody signatures?

Scott Paschke is focused on driving a business strategy that helps clients accelerate their research and discoveries using innovative tools and services offered by CDI Labs. Scott has over 20 years of experience in the biotechnology sector working with renowned R&D reagent companies. Prior to joining CDI Labs, Scott was Director of Business Development at Active Motif, and was President and Chief Technology Officer at Lake Placid Biologics. He also held leadership positions at Serologicals Corporation, Lake Placid Biologicals and Upstate Inc.  Scott received a BA in biology and a MA in biochemistry from State University College at Buffalo.

12:20 – 13:20
Networking Lunch
13:20 – 13:50

Spotlight Presentation

Engineering Unique Properties in Next-Gen Antibody Therapies

We will explore some of the cutting-edge advancements in our antibody discovery and engineering approaches to engineer unique properties in next generation therapeutic antibodies. With the aim to enhance specificity, potency, and to expand the therapeutic index, we will discuss how they hold the promise to significantly improve patient outcomes.

Jordon Wang is the Chief Operating Officer and Senior Vice President of Technology Development at AvantGen. The team is dedicated to accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Prior to joining AvantGen, Jordon served as VP of Technology Development and VP of Antibody Discovery at LakePharma, now part of Curia. He earned a B.S. in Biological Sciences and a Ph.D. in Cancer Biology at Stanford University.

Jordon Wang
13:50– 14:20
1-2-1 Meetings/Networking Break
14:20 – 14:50
1-2-1 Meetings/Networking Break
14:50 – 15:20
Spotlight Presentation

Discovery Reimagined: Tailoring Antibody Discovery to Your Wishlist

 A long wish list, short timeline, and limited budget. We have heard that before. Tune our antibody discovery engine to tackle your tall order. We work with you to tailor the screening campaign to generate the most data for the effort. This presentation focuses on challenges we have overcome for our clients including increasing hit count by isolating the best cells; combining multiple screens to measure blocking, cross-reactivity, and epitope specificity; ensuring specificity among closely related family members; and binding difficult membrane targets. We specialize in bespoke R&D antibody discovery services and are adding deeper collaborations for difficult targets.

Allison has been an essential part of Single Cell Technology since 2013, leading our efforts to improve and validate processes for cell isolation, antibody screening and amplification techniques, and helping turn our AbTheneum platform from a pipe dream into an impressively powerful pipeline. She now oversees Single Cell’s operations, keeping everything in and around the lab running smoothly while acting as an internal advocate for our clients. Allison is an AbTheneum expert — figuring out how to apply our tool to overcome challenges for each new project. She has a MS degree in Chemical Engineering and a BS in Biochemistry.

Allison Schulkins
15:20 – 15:50
1-2-1 Meetings/Networking Break
15:50 – 16:00
Afternoon Refreshments
16:35 – 17:35
Key considerations for target selection and proposal
  • Finding good and trained scientist
  • Animal models for translational research that truly reflect human disease condition

Over 15 years of experience in drug discovery research in Immuno-Oncology (IO) and Inflammation space. Trained as cellular immunologist with expertise in target proposal and validation, translational research, Mechanism of Action (MoA) studies, as well as assay development and High-Throughput Screening (HTS). I have a successful track record of publications in peer-reviewed journals and project leadership from hit identification to candidate selection point for both SMW and biologics targets. Currently I’m serving as Senior Director and Site Head for Neologics Bioscience for the San Diego site spearheading target biology and translational research initiatives. Prior to this, I held senior-level scientist positions at renowned organizations such as Novartis, Pharmacyclics (an Abbvie Company), and AnaptysBio. I have played a pivotal role in proposing multiple targets in both IO and inflammation space, some of which have progressed to both clinical and pre-clinical stages.

Bishnu Nayak
17:35– 18:35
Drinks-Canape Reception


Antibody Therapeutics Xchange | San Diego 2024